Lilly rides Mounjaro, Zepbound to better
Time:2024-05-21 18:10:45 Source:worldViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:College baseball notebook: Conference tournaments to decide NCAA automatic bids and many at
You may also like
- Minnesota Uber and Lyft driver pay package beats deadline to win approval in Legislature
- Trading Trump: Truth Social's first month of trading has sent investors on a ride
- Army veteran, 60, tucks into tinned Tesco meatballs 11 years past their use
- Braves 2B Ozzie Albies activated from injured list ahead of series versus Guardians
- Everybody may love Raymond, but Ray Romano loves Peter Boyle
- Jerry Seinfeld's commitment to the bit
- Oceanside Pier in San Diego is consumed by huge fire, forcing visitors to evacuate 1954
- REVEALED: George Soros is PAYING left
- Trump accepts a VP debate but wants it on Fox News. Harris has already said yes to CBS